This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

Angelucci, E., Astegiano, M., Baratelli, C., Biancone, L., Bironzo, P., Brancaccio, G., et al. (2019). AISF position paper on HCV in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 51(1), 10-23 [10.1016/j.dld.2018.09.022].

AISF position paper on HCV in immunocompromised patients

Fagiuoli, S;Puoti, M;
2019

Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.
Articolo in rivista - Articolo scientifico
HCV; Immunocompromised patients; Organ transplant;
English
2019
51
1
10
23
none
Angelucci, E., Astegiano, M., Baratelli, C., Biancone, L., Bironzo, P., Brancaccio, G., et al. (2019). AISF position paper on HCV in immunocompromised patients. DIGESTIVE AND LIVER DISEASE, 51(1), 10-23 [10.1016/j.dld.2018.09.022].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/304477
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
Social impact